FDA: lower ambien's dose to prevent drowsy driving
(HealthDay)—The U.S. Food and Drug Administration has approved new, lower-dose labeling for the popular sleep drug Ambien (zolpidem) in an effort to cut down on daytime drowsiness that could be a hazard ...
Medications
May 15, 2013 |
not rated yet |
0
Drug manufacturer agrees to $500 million penalty (Update)
A subsidiary of India's largest pharmaceutical company has agreed to pay a record $500 million in fines and penalties for selling adulterated drugs and lying to federal regulators in a case that is part of an ongoing crackdown ...
Medications
May 13, 2013 |
not rated yet |
0
FDA denies request to block generic painkiller
In a surprise move, federal health regulators have denied a request by Endo Health Solutions to block generic versions of its painkiller Opana ER, which the company argued can be more easily abused than its branded product.
Medications
May 10, 2013 |
not rated yet |
0
FDA warns pregnant women about migraine drugs
(HealthDay)—Pregnant women who struggle with migraine headaches should never use medicines containing the ingredient valproate because they can lower the IQ scores of their children, the U.S. Food and Drug ...
Medications
May 06, 2013 |
not rated yet |
0
Fearing abuse, US blocks generic OxyContin (Update)
U.S. health regulators will require generic versions of the best-selling painkiller OxyContin to include recent formulation changes designed to make the pill harder to abuse.
Medications
Apr 16, 2013 |
not rated yet |
1
India's rejection of drug patent could reverberate
The India Supreme Court's rejection of a patent for an improved version of a costly cancer drug by Novartis AG could have big implications for the world's largest drugmakers. ...
Medications
Apr 01, 2013 |
not rated yet |
0
India's top court to deliver Novartis judgment
India's Supreme Court is to rule Monday on a landmark patent case involving Swiss drugmaker Novartis AG that focuses on demands by major companies that their investments be protected, against Indian companies ...
Medications
Mar 31, 2013 |
not rated yet |
0
AstraZeneca settles legal dispute with Watson (Update)
(AP)—Anglo-Swedish pharmaceutical company AstraZeneca has settled a patent dispute with Watson Laboratories, Inc., removing a threat against its top-selling cholesterol-control drug, Crestor.
Medications
Mar 25, 2013 |
not rated yet |
0
Court: Can generic drug maker be sued over design?
The Supreme Court will soon decide whether generic drug manufacturers can be sued in state court for a drug's design defects after federal officials approved the brand-name version.
Medications
Mar 19, 2013 |
not rated yet |
0
Pfizer painkiller gets longer patent protection (Update)
Drugmaker Pfizer Inc. said Tuesday that a new patent on one of its top drugs, anti-inflammatory painkiller Celebrex, extends its U.S. patent protection by 18 months, potentially bringing the company a few billion dollars ...
Medications
Mar 05, 2013 |
not rated yet |
0
India rejects Bayer plea against cheap cancer drug (Update)
India's patent appeals office has rejected Bayer AG's plea to stop the production of a cheaper generic version of a patented cancer drug in a ruling that health groups say is an important precedent for getting ...
Medications
Mar 05, 2013 |
5 / 5 (4) |
3
Bayer vows to fight for patent on anti-cancer drug in India
German pharmaceuticals giant Bayer, maker of Aspirin, vowed Monday to fight a ruling by the patent authorities in India allowing a local company to produce and sell a generic copy of its anti-cancer drug Nexavar.
Medications
Mar 04, 2013 |
not rated yet |
0
Myth that UK supply of innovative new pharma drugs is drying up
The widely held belief that the UK supply of innovative new medicines has conspicuously dwindled in recent decades, is not borne out by the evidence, reveals research published in the online journal BMJ Open.
Medications
Feb 20, 2013 |
not rated yet |
0
Most NCDs could be treated with small number of cheap generic drugs and within existing budgets
In the fifth Series paper, researchers led by Professor Hans Hogerzeil from the University of Groningen in the Netherlands say that most NCDs could be treated with a small range of inexpensive, off-patent medicines, and suggest ...
Medications
Feb 11, 2013 |
not rated yet |
0
Hoping to ease shortage, FDA fast-tracks generic form of cancer drug
(HealthDay)—Seeking to ease potentially dangerous shortages of a key cancer drug, the U.S. Food and Drug Administration on Monday announced it had fast-tracked the approval of the first generic form of ...
Medications
Feb 04, 2013 |
not rated yet |
0
